Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brain Cancer
Researchers from Medical University of South Carolina provide details of new studies and findings in the area of brain cancer
May 19th, 2009
Researchers in the United States conducted a study "To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T). Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then. after 2-7 days, a second examination with the other agent." "Contrast administration (volume, rate). sequence parameters (T1wSE;T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation....
Source: Cancer Weekly (2009-05-19)
|
